On February 8, 2017 Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, reported that it will feature three new preclinical research poster presentations during the 2017 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held April 1 – 5, 2017, in Washington, D.C (Press release, Five Prime Therapeutics, FEB 8, 2017, View Source [SID1234517658]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Number and Title: #613, "Development of FPA154, a Novel Tetravalent Anti-GITR Antibody, for the Treatment of Solid Tumors"
Session Title: T-cell Immunity to Cancer: New Progress
Session Date and Time: Sunday, April 2, 2017, 1 – 5 p.m.
Location: Convention Center, Halls A-C, Poster Section 26, Poster Board Number: 17

Abstract Number and Title: #1599, "Antibody-Based Inhibition of CSF-1R as a Component of Combination Immunotherapy in Preclinical Models"
Session Title: Cytokines: The First Modern Immunotherapies
Session Date and Time: Monday, April 3, 2017, 8 a.m. – 12 p.m.
Location: Convention Center, Halls A-C, Poster Section 26, Poster Board Number: 7

Abstract Number and Title: #2633, "Identification of Novel T Cell Co-Inhibitory and Co-Stimulatory Receptors from Screening a Comprehensive Library of Extracellular Proteins"
Session Title: Checkpoints 2: Small-Molecule Inhibitors
Session Date and Time: Monday, April 3, 2017, 1- 5 p.m.
Location: Convention Center, Halls A-C, Poster Section 25, Poster Board Number: 22